Home » Innovation » Tech Transfer & Valorization

Tech Transfer & Valorization

Évaluer et sélectionner les projets

A dedicated valorisation committee

Immun4Cure has a dedicated valorisation committee composed of founding members and partners, whose mission is to evaluate and select projects from research teams within the institute perimeter that will be submitted for early-stage funding to the Montpellier University Innovation Cluster (PUI) and for further development to the SATT AxLR. This committee will also be able to issue an opinion on the most appropriate commercialisation route, i.e. the creation of start-ups or the transfer of operating licences to an existing company.

Projects receiving early-stage/maturation funding will be presented by SATT AxLR, as a member of the consortium, to the Combio National Acceleration Strategy (SNA) dedicated to biotherapies and the bioproduction of innovative therapies, which aims to make France the leading European country for the development and production of new biomedicines.

The early-stage and maturity funding provided by SATT AXLR and SNA Combio will enable preclinical phases to be accelerated, allowing clinical phases to be reached more quickly. With around ten biotech start-ups already created, we anticipate that, thanks to the IHU, there will be an increase in the number of companies created that will bring the solutions developed in Montpellier to market. Thus, in addition to being an accelerator for therapeutic solutions, the IHU Immun4cure will have an impact on the economic development of the region.

Philippe Nérin,

Chairman of SATT AxLR

Bridging the gap between scientific discovery and patient care supporting the maturation and valorization of your innovations

Our mission: As a true driver of innovation, IHU Immun4Cure transforms scientific excellence into tangible solutions for patients. We identify pioneering projects and support them from the proof-of-concept stage through to industrial transfer or start-up creation.

A Dedicated Valorization Committee

The Valorization Committee evaluates and supports your projects throughout the maturation process. It is composed of the valorization structures of the founding members (Montpellier University Hospital, Inserm, and Montpellier University) and expert valorization partners (SATT AxLR) and external industrial experts.

Its role: to steer projects toward the most suitable valorization path (namely spin-off creation or licensing) and to facilitate access to pre-maturation and maturation funding.

The maturation process

Detection: early identification of innovations within our research areas.
Assessment: IP analysis and market potential. Submission for funding to the Montpellier University Innovation hub (PUI).
Maturation: technical development and proof of concept (PoC) with SATT AxLR.
Valorization: technology transfer via licences or creation of spin-offs.

Innovative Therapeutic Approaches

🎯

Cell Therapies
CAR-T cells, MSCs, extracellular vesicles.

🧬

RNA Technologies
Development of RNA-based therapeutic strategies.

🔬

Protein & Antibody Engineering
Design and development of Nanobodies (VHH) and Peptibodie.

⚗️

GMP Bioproduction
ATMPs for clinical applications.

🩺

Precision Medicine
Biomarkers, high-resolution molecular profiling, and predictive modeling.

Looking to bring your innovation to life ?

Contact our team to discuss your innovation and identify the best way to develop it within our ecosystem.